Abstract
There is no early diagnosis marker for gastric cancer even though the gastric cancer is the second cause of deaths in East Asia. The aim of the current research is to develop a new diagnostic marker of gastric cancer. Commercially available ELISA kits were used to evaluate the peptide levels in plasma collected from Korean healthy and gastric cancer patients. About 1.5 fold decreased plasma cholecystokinin levels were measured in gastric cancer patients (n=75) than in healthy controls (n=36). Plasma cholecystokinin has no age, sex, and disease-dependent variation in control and patients sample. Receiver-operating characteristic curve analysis assessing the performance of cholecystokinin levels as the sensitivity of 94.7% and specificity of 100 % compared to healthy controls. These findings suggest plasma cholecystokinin as a useful biomarker for diagnosis of gastric cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 14-20 |
| Number of pages | 7 |
| Journal | Biochip Journal |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Mar 2017 |
Bibliographical note
Publisher Copyright:© 2016, The Korean BioChip Society and Springer-Verlag Berlin Heidelberg.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biomarker
- CCK
- ELISA
- Early diagnosis
- Gastric cancer
Fingerprint
Dive into the research topics of 'Cholecystokinin as a potent diagnostic marker for gastric cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver